Skip to main content

Home/ Health and Fitness Club/ Group items matching "Global-100-award" in title, tags, annotations or url

Group items matching
in title, tags, annotations or url

Sort By: Relevance | Date Filter: All | Bookmarks | Topics Simple Middle
pharmacybiz

HayMax wins 2023 'Global 100' awards | UK News - 0 views

  •  
    HayMax, manufacturer of organic, drug-free allergen barrier balms for hay fever, dust, and pet allergies, has recently won the 2023 Global 100 awards. The HayMax balm, applied around nostril rims and eye bones, is an innovative allergen blocker against pollen, dust, and pet allergens entering the body. Independent university research confirms it traps over a third of pollen, along with dust mites and pet dander, before they enter the body, according to HayMax. The drug-free balm is Soil Association-certified organic, comprising 100 per cent natural ingredients. Safe for children, pregnant, and breastfeeding women, it holds the Vegetarian Society Approved trademark. This award has come as a complete surprise to us at HayMax," said HayMax MD, Max Wiseberg. "Being held in such high regard through this global recognition is truly delightful." "The Global 100 aims to offer readers insight into firms that excel in their chosen specialties, and the award underscores hard work and innovation of various companies," said its organisers.
pharmacybiz

UK approves CStone's Sugemalimab for non-small cell lung cancer treatment - 0 views

  •  
    The Medicines and Healthcare products Regulatory Agency (MHRA) has awarded marketing authorisation to CStone Pharmaceuticals for sugemalimab (Eqjubi) as a first-line treatment for non-small cell lung cancer (NSCLC) in the UK. NSCLC is the most common form of lung cancer, accounting for around 80 to 85 out of 100 cases. Sugemalimab is now approved as a first-line treatment, in combination with platinum-based chemotherapy, for adult patients with metastatic NSCLC who do not have EGFR-sensitive mutations or ALK, ROS1, or RET genomic alterations. This UK approval follows its recent authorisation by the European Commission, marking the second international approval for sugemalimab. CStone's CEO Dr. Jason Yang described the UK's approval as a significant milestone in their global expansion strategy. "Sugemalimab is the first domestic anti-PD-L1 antibody to receive approval outside of China and has already entered the world's second-largest pharmaceutical market, the EU. "Now, with the UK approval, sugemalimab continued to expand its presence in the European market. The long-term survival data, recently presented at this year's ESMO Congress, further confirmed sugemalimab's value in the frontline treatment landscape for metastatic NSCLC," he said.
1 - 2 of 2
Showing 20 items per page